library_construction_protocol: Spleens from each genotype and treatment group (n=2 per condition) were pooled, and single cell suspensions were stained with fluorophore-conjugated antibodies as well as TotalSeqB hashtag antibodies specific against mouse CD45 and MHC-I (BioLegend) to maintain sample identity (B0301 = Control untreated, B0302 = Control LPS+profilin, B0303 = Smc3ΔDC untreated, B0304 = Smc3ΔDC LPS+profilin. Successful cDC activation was confirmed by flow cytometric analysis of CD86 upregulation. Cell sorting was performed on FACSAria II (BD Biosciences) at the Cytometry & Cell Sorting Laboratory at NYUGSoM. 6,500 (B0301-0303) or 4,000 (B0304) cDC1s (Live singlets IgD- TCR-β- NK1.1- CD11c+ MHC-II+ XCR1+ SIRPα-) and 8,500 cDC2s (Live singlets IgD- TCR-β- NK1.1- CD11c+ MHC-II+ XCR1- SIRPα+) from each sample were sorted and pooled together in 50 μl PBS containing 10% FBS. The resulting cell mixture was prepared according to the 10X Genomics protocol at the Genome Technology Center at NYUGSoM.